신테카바이오

226330KOSDAQ소프트웨어 개발 및 공급업

52.8 / 100

Reference Date: 2026-06-10

Financial Score14.5 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure14.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Plunged 30.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Synetica Bio is a biotech venture company established in 2009, specializing in AI-driven drug discovery platforms and genomics big data solutions. Its core services include DeepMatcher® hit screening, personalized neoantigen identification (NEO-ARS®), and genomic precision medicine (NGS-ARS®), with revenue generated through both platform services and in-house drug pipelines. The company leverages its supercomputing infrastructure and partnerships to maintain a competitive edge in the industry.

Number of Employees

49people

Average Salary

61.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 13.624.0Point

PBR

1.49Industry Average 1.022.5Point

Higher than industry avg (caution)

ROE

-61.27Industry Average 1.100.0Point

Well below industry avg

Debt Ratio

7.90Industry Average 7.934.0Point

In line with industry avg

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲1367.3% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.1% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 6Neutral 0Negative 0Average Sentiment Score 85

Positive
신테카바이오, 중기부 지원 지역혁신선도기업육성 과제 최종 선정
신테카바이오가 중소벤처기업부의 핵심 R&D 과제에 선정되어 기술 경쟁력 강화 기회를 얻었다.
Positive
AI신약 기업 신테카 "이제 자체 개발…전략 전환"
신테카바이오의 자체 개발 AI 신약 파이프라인 공개로 인해 임상 진입 전략 전환이 긍정적인 시장 반응을 이끌 것으로 예상됩니다.
Positive
신테카바이오, 신약 파이프라인 7개 공개…"자체 임상 진입 목표"
신테카바이오가 AI 기반 신약 파이프라인 7개를 공개하며 직접 임상 진입을 목표로 함으로써 개발 효율성과 성공 가능성을 높여 긍정적인 시장 반응을 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,950Won52-week high 6,90352-week low 1,950

1-month return0.0Point

1m -30.85% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 2Neutral 5Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-05-29
Positive[기재정정]단일판매ㆍ공급계약체결2026-05-28
Positive최대주주변경을수반하는주식담보제공계약체결2026-05-28
Neutral주식등의대량보유상황보고서(일반)2026-05-18
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-18